On April 12, 2023 at 09:51:09 ET an unusually large
$799.92K block of Put contracts in Medtronic
(MDT) was sold,
with a strike price of $72.50 / share, expiring in 65 days (on June 16, 2023).
Fintel tracks all large options trades, and the premium spent on this trade was 2.32 sigmas above the mean, placing it in the 99.73 percentile of all recent large trades made in MDT options.
This trade was first picked up on Fintel’s real time Unusual Option Trades
tool, where unusual option trades are highlighted.
Analyst Price Forecast Suggests 11.73% Upside
As of April 6, 2023,
the average one-year price target for Medtronic is $90.50.
The forecasts range from a low of $77.77 to a high of $105.00.
The average price target represents an increase of 11.73% from its latest reported closing price of $81.00.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Medtronic
is $30,781MM, an increase of 0.03%.
The projected annual non-GAAP EPS
is $5.32.
What is the Fund Sentiment?
There are 3195 funds or institutions reporting positions in Medtronic.
This is an increase
of
24
owner(s) or 0.76% in the last quarter.
Average portfolio weight of all funds dedicated to MDT is 0.62%,
an increase
of 11.24%.
Total shares owned by institutions decreased
in the last three months by 0.50% to 1,259,143K shares.
The put/call ratio of MDT is 0.76, indicating a
bullish
outlook.
What are Large Shareholders Doing?
VTSMX – Vanguard Total Stock Market Index Fund Investor Shares
holds 40,441K shares
representing 3.04% ownership of the company.
In it’s prior filing, the firm reported owning 39,665K shares, representing
an increase
of 1.92%.
The firm
decreased
its portfolio allocation in MDT by 9.38% over the last quarter.
Massachusetts Financial Services
holds 35,400K shares
representing 2.66% ownership of the company.
No change in the last quarter.
VFINX – Vanguard 500 Index Fund Investor Shares
holds 30,726K shares
representing 2.31% ownership of the company.
In it’s prior filing, the firm reported owning 30,120K shares, representing
an increase
of 1.97%.
The firm
decreased
its portfolio allocation in MDT by 9.55% over the last quarter.
Wellington Management Group Llp
holds 29,857K shares
representing 2.24% ownership of the company.
No change in the last quarter.
Capital Research Global Investors
holds 28,815K shares
representing 2.17% ownership of the company.
In it’s prior filing, the firm reported owning 28,777K shares, representing
an increase
of 0.13%.
The firm
decreased
its portfolio allocation in MDT by 11.35% over the last quarter.
Medtronic Declares $0.68 Dividend
On March 2, 2023 the company declared a regular
quarterly dividend of $0.68 per share ($2.72 annualized).
Shareholders of record as of March 24, 2023
will receive the payment on April 14, 2023.
Previously, the company paid $0.68 per share.
At the current share price of $81.00 / share,
the stock’s dividend yield is 3.36%.
Looking back five years and taking a sample every week, the average dividend yield has been
2.32%,
the lowest has been 1.77%,
and the highest has been 3.57%.
The standard deviation of yields is 0.44 (n=237).
The current dividend yield is
2.39 standard deviations
above
the historical average.
Additionally, the company’s dividend payout ratio is 0.89.
The payout ratio tells us how much of a company’s income is paid out in dividends. A payout ratio of one (1.0)
means 100% of the company’s income is paid in a dividend.
A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend – not a
healthy situation.
Companies with few growth prospects are expected to pay out most of their income in dividends, which typically
means a payout ratio between 0.5 and 1.0.
Companies with good growth prospects are expected to retain some earnings in order to invest
in those growth prospects, which translates to a payout ratio of zero to 0.5.
The company’s 3-Year dividend growth rate is 0.26%,
demonstrating that it has increased its dividend over time.
Medtronic Background Information
(This description is provided by the company.)
Medtronic plc, headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
